Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears
Simply Wall St reports Myriad Genetics (MYGN) shares fell nearly 47% in a day after results showed a revenue reset and loss fears. Q2 revenue was $190.7m, down 11% year over year, and full-year 2026 sales guidance was cut to $770m to $790m. Adjusted EBITDA guidance was suspended.
How this was made
The 30-second read
Why it matters
The guidance reset centers on weaker pricing/reimbursement translating into lower revenue and margin visibility, while adjusted earnings and adjusted EBITDA guidance are suspended.
Market read
Traders likely reprice MYGN on reduced sales guidance, lower gross margin guidance, and suspended profitability targets, increasing the probability of further downside volatility.
What to watch
The article cites early customer interest in Prolaris+ AI and product expansion, but does not quantify whether these will improve average revenue per test or gross margin in 2026.
Background
Myriad is positioned as a precision oncology and molecular diagnostics company, with a thesis tied to adoption, reimbursement, and margin improvement.
Ticker impact
Myriad Genetics reported Q2 revenue of $190.7m and cut full-year 2026 sales guidance to $770m-$790m while suspending adjusted earnings guidance.
Bearish near-term bias, with elevated volatility likely until revenue per test and gross margin stabilize.
The newest disclosed facts are the Q2 revenue decline, guidance cut, gross margin guidance step-down, and suspension of adjusted earnings/EBITDA guidance, all of which directly worsen profitability visibility.
Market effects
Reinforces broader diagnostics/precision-oncology investor skepticism around payer reimbursement and pricing power.
Primarily impacts US biotech sentiment, especially Nasdaq-listed molecular diagnostics names.
Limited direct global spillover, but contributes to international read-across on reimbursement-driven margin risk.
Counterpoint
Oncology volume growth (MyRisk +10%) and expansion of Precise MRD coverage could eventually offset pricing pressure if reimbursement catches up.
Key entities
- companyMyriad Genetics
Nasdaq-listed molecular diagnostics and precision medicine company whose Q2 results and 2026 guidance were reset.
- productMyRisk
Hereditary cancer test mentioned as having 10% volume growth in the quarter.
- productPrecise MRD
Minimal residual disease offering expanded into colorectal and renal cancers, and breast cancer coverage pushed to MolDX.
- productProlaris+ AI
Prostate cancer test launched with early customer interest, tied to an AI-driven approach.
